Archives
GOT1 Inhibition by Ziprasidone Alters Redox and Glutamine Pa
2026-05-14
GOT1 Inhibition by Ziprasidone: Redox and Glutamine Metabolism Disruption in PDAC
Study Background and Research Question
Pancreatic ductal adenocarcinoma (PDAC) remains among the deadliest cancers, with a 5-year survival rate of just 8% in the United States (source: paper). The persistence and progression of PDAC are tightly linked to metabolic reprogramming—a hallmark of cancer—whereby tumor cells increasingly rely on altered nutrient pathways for survival and growth. Notably, the glutamine metabolic pathway, and its regulation through glutamate-oxaloacetate transaminase 1 (GOT1), has emerged as a critical node in PDAC metabolism. GOT1 catalyzes the conversion of aspartate to oxaloacetate, feeding into a cascade that ultimately supports NADPH production and maintains redox homeostasis. Despite the centrality of GOT1 in sustaining PDAC proliferation and redox balance, few selective GOT1 inhibitors have been identified. This gap prompted the current investigation: Can pharmacological targeting of GOT1 disrupt glutamine metabolism, redox equilibrium, and thereby suppress PDAC cell growth?Key Innovation from the Reference Study
The reference study advances the field by revealing that ziprasidone—a molecule previously known for its psychiatric applications—acts as a non-competitive inhibitor of GOT1. Unlike earlier GOT1 inhibitors identified through high-throughput screening or natural products (e.g., aminooxyacetate, Aspulvinone O), ziprasidone directly impairs GOT1 activity, leading to substantial changes in glutamine metabolism and the redox state in PDAC cells (source: paper). This novel mechanistic insight expands the therapeutic landscape for PDAC by targeting metabolic vulnerabilities.Methods and Experimental Design Insights
To elucidate the role of ziprasidone in modulating glutamine metabolism, the authors employed a multi-pronged approach:- Biochemical assays to determine GOT1 inhibition kinetics and specificity.
- Genetic knockdown of GOT1 to probe whether the cytotoxic effects of ziprasidone are GOT1-dependent.
- In vitro evaluation of cell proliferation, migration, and apoptosis in PDAC cell lines (notably SW1990).
- Metabolomics profiling to map the reprogramming of glutamine metabolism and related redox pathways.
- In vivo studies using SW1990 xenograft tumor models in mice to assess antitumor efficacy.
Core Findings and Why They Matter
The study’s findings are significant on multiple fronts:- Ziprasidone is a non-competitive GOT1 inhibitor: Enzyme kinetics demonstrated that ziprasidone inhibits GOT1 activity without competing for the substrate-binding site. This mechanistic property may offer selectivity and reduced off-target effects compared to classical competitive inhibitors (source: paper).
- Suppression of PDAC proliferation and tumor growth: Both in vitro (cell culture) and in vivo (xenograft) models showed that ziprasidone impedes cell proliferation and induces apoptosis in PDAC, with significant tumor growth reduction observed in treated mice (source: paper).
- Redox imbalance as a mechanism of action: Ziprasidone-induced GOT1 inhibition disrupts the conversion of aspartate to oxaloacetate, leading to lower NADPH/NADP+ ratios and increased reactive oxygen species (ROS) accumulation—key oxidative stress biomarkers in cancer research. This redox imbalance is central to the compound’s cytotoxicity (source: paper).
- Glutamine metabolism reprogramming: Metabolomics analyses revealed that targeting GOT1 alters the flux of glutamine-derived metabolites, affecting key nodes in the tricarboxylic acid (TCA) cycle and amino acid biosynthesis. These changes undermine the metabolic adaptability of PDAC cells.
- GOT1 dependency validated: Genetic knockdown of GOT1 blunted the anti-proliferative effects of ziprasidone, confirming that the observed phenotypes are specifically mediated through GOT1 inhibition.
Comparison with Existing Internal Articles
Recent internal articles have provided protocol-level insights and workflows for studying redox homeostasis and metabolic reprogramming in cancer models:- L-Glutathione Reduced: Applied Workflows in Redox and Cancer offers detailed protocols for deploying reduced glutathione as both a redox buffer and a glutathione S-transferase substrate, aligning with the need for robust redox assessments in metabolic oncology research.
- L-Glutathione Reduced: Optimizing Redox Workflows in Cancer Research highlights the centrality of reduced glutathione in tracking oxidative stress biomarkers and troubleshooting redox modulation in translational oncology models.
- The reference study’s focus on NADPH/NADP+ redox ratios and ROS levels in PDAC cells complements these internal resources, suggesting a convergent utility for endogenous antioxidant tripeptides like L-Glutathione Reduced in validating redox-dependent drug mechanisms.
Protocol Parameters
- assay | NADPH/NADP+ ratio measurement | units vary (typically pmol/µg protein) | quantifies redox state in response to metabolic inhibition | essential for linking GOT1 activity to redox homeostasis | paper
- assay | ROS (reactive oxygen species) quantification | relative fluorescence units (RFU) | monitors oxidative stress biomarker accumulation | distinguishes cytotoxicity mechanisms in cancer cells | paper
- assay | Glutathione (GSH/GSSG) ratio analysis | µmol/mg protein | assesses antioxidant system capacity | supports studies of glutathione-dependent redox buffering | workflow_recommendation
- assay | GST (glutathione S-transferase) activity assay | U/mg protein | evaluates metabolic enzyme regulation under redox stress | relevant for redox and detoxification research | workflow_recommendation
Limitations and Transferability
While the study demonstrates the efficacy of ziprasidone as a GOT1 inhibitor in both cell culture and mouse xenograft models, several limitations warrant consideration:- Translational uncertainty: The antitumor effects, though significant in preclinical models, require further validation in primary PDAC samples and clinical settings (source: paper).
- Redox specificity: While redox imbalance is implicated as a mechanism, the broader impact on non-cancerous tissue redox homeostasis and potential off-target effects of ziprasidone remain to be fully elucidated.
- Metabolic adaptability: Cancer cells can rewire metabolic pathways in response to targeted inhibition, potentially leading to resistance. Combining GOT1 inhibition with other redox modulators, such as reduced glutathione, may be necessary for sustained efficacy (workflow_recommendation).